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Abstract
Access to antiretroviral therapy (ART) is increasing in resource-limited settings (RLS) and can
successfully reduce HIV-related morbidity and mortality. However, virologic failure and
development of viral drug resistance can result in reduced treatment options and disease
progression. Additionally, transmission of resistant virus, and particularly multi-drug resistance,
could become a public health concern. This study evaluated treatment success and development of
ART drug resistance after short-term treatment among patients attending the Comprehensive HIV
Care Centre (CCC) of Coast Province General Hospital, Mombasa, Kenya. One hundred and fifty
HIV-infected individuals receiving ART were consecutively recruited to participate in the study.
After determination of plasma viral load, patients with detectable viral load levels were subjected
to genotypic drug resistance testing. At the time of sampling, 132 of the 150 participants were on
ART for more than 6 months (median 21 months, IQR = 12–26). An efficient viral load reduction
to below 50 copies/ml was observed in 113 (85.6%) of them. Of the 19 patients with a detectable
viral load, sequencing of the protease (PR) and reverse transcriptase (RT) gene was successful in
16. Eleven (11) of these 16 patients were infected with a subtype A1 virus. Major PR mutations
were absent, but mutations associated with drug resistance in RT were detected in 14 of the 16
patients (87.5%). High-level resistance against at least 2 drugs of the ART regimen was observed in
9/14 (64.3%). The 3TC mutation M184V and the NNRTI mutation K103N were most frequent but
also the multi-drug resistance Q151M and the broad NRTI cross-resistance K65R were observed.
The results of this study revealed a high rate of treatment success after short term ART in patients
treated at a public provincial hospital in a RLS. Nevertheless, the observed high risk of accumulation
of resistance mutations among patients failing treatment and the selection of multi-drug resistance
mutations in some, remains of great concern for future treatment options and potential
transmission to partners.
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Introduction
Recent data show an HIV prevalence in Kenya of 7.4%,
resulting in 1.4 million Kenyans living with HIV [1]. An
estimated 190,000 HIV-infected Kenyans receive ART,
representing 44% of those in need of treatment [1]. At the
Comprehensive HIV Care Centre (CCC) in Mombasa, the
decision on when to start or switch treatment is based on
clinical and immunological parameters [2,3]. Information on the rate of treatment failure and the development
of drug resistance in public hospitals in RLS, where treatment decisions are guided by clinical parameters and CD4
count only, is limited. Virologic treatment failure and
accompanying resistance are of concern with regard to the
risk of disease progression and potential transmission of
drug resistant virus to partners. The aim of this study was
to assess, in a cross-sectional survey, the rate of viral suppression and drug resistance among individuals receiving
ART.

Materials and methods
From the patients attending the CCC in Coast Province
General Hospital, Mombasa, a total of 150 consecutive
patients, over 18 years of age and receiving ART, were
asked to participate in this surveillance study by a trained
adherence counsellor. Fifty (50) patients were recruited in
April 2006, 100 patients were recruited in May 2007. Participants gave written informed consent, and refusal to
participate did not influence the standard of care. Ethical
approval was obtained from the Kenyatta National Hospital Ethics and Research Committee.
Using a structured questionnaire, basic socio-demographic and clinical data was obtained from each participant. ART adherence was measured by self-report and pill
count over the last month and recorded as satisfactory
(>95%) or unsatisfactory (<95%). Ten (10) ml of EDTA
blood was collected for CD4 cell count (FACScount Becton & Dickinson Immunocytometry, Oxford, UK). The
remainder of the blood was centrifuged to collect plasma,
which was stored at -80°C until processing for viral load
measurement and genotyping.
Plasma HIV RNA quantification was performed, using the
Ultrasensitive Cobas Amplicor HIV-1 Monitor Test version 1.5 (Roche Diagnostics, Basel, Switzerland) with a
lower detection limit of 50 copies/ml.
Extraction, amplification and genotyping of HIV RNA was
performed by nested RT-PCR and an in-house sequencing
assay as described elsewhere [4]. The interpretations of
genotyping data and subtyping were performed using
Smartgene™ HIV software packages (Integrated Database
Network System, Smartgene, Zug, Switzerland). Selection
of drug resistance mutations was based on the recent
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update of the IAS-USA list [5]. Sequences were submitted
to Genbank [Genbank EU872121–EU872135 and
878548 for PR and EU872136–EU872150 and 878549
for RT].
All statistical analyses were performed using SPSS 15.0
(SPSS, Illinois, USA).

Results
The median age of the participants was 37 years (IQR =
32–43) with 69% being women (Table S1; Additional File
1). The majority of participants (67%) were in WHO clinical stage 3 or 4 [6]. Baseline CD4 count was available for
146 participants with a median of 112 cells/mm3 (IQR =
63–184). A combination of d4T+3TC+NVP was the most
commonly prescribed first-line regimen (n = 79), followed by d4T+3TC+EFV (n = 63), AZT+3TC+NVP (n = 5),
AZT+3TC+EFV (n = 2), and d4T+ddI+EFV (n = 1). Patients
receiving their first ART regimen had been treated for a
median of 17 months (IQR = 10–24). In 16 patients treatment was changed after a median of 18 months (IQR =
13–26) by substituting one (n = 7), two (n = 5) or three
(n = 4) drugs because of adverse events (n = 8), start of
anti-tuberculosis treatment (n = 1), unavailability of drugs
(n = 1), or immunological failure (n = 6). The 6 patients
with immunological failure were switched to a LPV/r
based regimen as recommended by the Kenyan national
guidelines [2].
Eighteen of the 150 patients initiated ART less than 6
months (median 3.5 months, IQR = 2–6) before blood
collection and were excluded from further analyses. For
the remaining 132 patients, an undetectable viral load
was seen in 110 (87.3%) of the 126 patients without treatment changes or with treatment changes for other reasons
than immunological failure and in 3 of the 6 patients in
whom the treatment was changed because of immunological failure. The median viral load of the 19 patients with
ongoing viral replication was 3,060 copies/ml (IQR =
294–21,000). A detectable viral load was not significantly
associated with the mean duration of ART (P = 0.42) or
mean baseline CD4 (P = 0.18). A significantly higher
mean CD4 count was seen in patients with an undetectable viral load (n = 113, mean = 344 cells/mm3) compared
to those with a detectable viral load (n = 19, mean = 253
cells/mm3) (P = 0.03). However, the mean increase in
CD4 from baseline level was not significantly different
between the two groups (P = 0.33). Seventy-four patients
(58.6%) reported to have satisfactory adherence, which
was significantly associated with treatment success (P =
0.02).
Genotyping was attempted for all 19 participants with a
detectable viral load and was successful for PR in 17
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(89.5%) and for RT in 16 (84.2%). Amplification failures
were due to low viral loads (79, 81 and 115 copies/ml).
The subtype distribution for these 16 samples was as follows: subtype A1 (n = 11), CRF16_AD (n = 2), C (n = 1),
D (n = 1) and a new recombinant of A1 and D (n = 1). No
major PR resistance mutations were seen in any of the
sequences, but a mean of 4 minor PR mutations were
observed per sample (data not shown). Resistance mutations in RT were detected in 14 out of the 16 patients.
Overall, the V184M was most commonly observed (n =
12), followed by K103N (n = 9). In one patient the multidrug resistant Q151M mutation was seen and two
patients carried virus with a K65R mutation, all three combined with V184M (Table S2; Additional File 2). In 10
patients a combination of V184M and at least one mutation conferring to NNRTI-class resistance was observed.
Two patients who harboured wild type virus had a viral
load of 533 and 1,380 copies/ml after 23 and 26 months
of treatment respectively.

Discussion
Intensive campaigns to improve availability of ART worldwide is paying off and most African countries are currently
able to provide first-line ART regimens to a considerable
number of HIV-1 infected individuals in need of treatment. Efforts to scale-up laboratory facilities for treatment
monitoring in these patients however are running behind.
A random sample survey is often the only way to assess
treatment efficacy and the selection of drug resistance in
treatment programs in Africa. The information obtained
from these surveys is important for eventual future adaptation of treatment strategies. Moreover, resistance data
obtained from these surveys will be crucial in evaluating
the value of second-line regimens in Africa where only
limited drugs are available.
In this study, 85.6% of the patients receiving ART ≥ 6
months had a VL<50 copies/ml. These figures are comparable to what has been published for other African regions
[7-10]. The high treatment success rate seen in this study
might be partly due to a bias because of possible selection
of patients who attend the CCC more regularly. These
patients could be more motivated and having a better
treatment adherence. Although the total number of
patients was small, a significant correlation between
adherence and treatment success was demonstrated.
Despite the overall high efficacy of ART treatment regimens, a significant accumulation of resistance mutations
was observed in patients with a detectable viral load at 6
months or more after treatment initiation. Though we
cannot excluded that some of these mutations were
already present at baseline, we assume that most of them
were selected during treatment. As mutations can only be
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selected in the presence of the drug, their detection
excludes the poor-intake of medication as the main reason for failure.
The combinations of AZT/d4T+3TC+EFV/NVP are extensively used as a first-line regimen in RLS [11]. Despite
known toxicity of d4T, this drug is still commonly used in
RLS as a component of the low-cost generic fixed dose
combinations. 3TC, EFV and NVP have a low genetic barrier towards resistance and it is therefore not unexpected
that, in accordance with the results of other studies, the
3TC mutation M184V and the NNRTI mutations K103N,
190G and 181C are frequently observed in case of treatment failure [8,12]. The high percentage (62.5%) of
patients with a combination of M184V mutations and at
least one NNRTI resistance associated mutation, as well as
the selection of the broad NRTI cross-resistance mutations
Q151M and K65R in 3 patients are worrying.
K65R mutations have previously been described among
populations with similar subtypes [13]. However, this was
mainly among patients receiving a TDF containing regimen which is known to induce the K65R mutation [14].
However, the selection of K65R under a d4T containing
regimen seems to be more common among non-B subtypes as observed by others [15,16]. Despite the presence
of the thymidine analogues AZT or d4T in most of the regimens, thymidine analogue mutations (TAMs) were infrequently observed.
Accumulation of mutations against drugs from different
drug classes and/or the presence of broad cross-resistance
mutations will jeopardize the effectiveness of the NRTI
backbone of second-line regimens that often include ABC
and TDF. Moreover, the limited availability and the high
cost of boosted PIs force clinicians in RLS to recycle
NNRTIs in the second-line regimen. Based on the resistance data from this study, we can assume that the effect of
such a second-line regimen will be at the most temporary.
The small number of patients on a second-line regimen
that were included and the limited time period between
initiation of this regimen and the date of sampling, did
not allow us to make conclusions about the efficacy of second-line regimens.
In conclusion, the results of this observational study show
that effective first-line ART in clinical care centres with
limited resources is feasible. However, the resistance data
point out the danger of the absence of viral monitoring,
with regard to the accumulation of resistance mutations.
Besides high quality adherence counselling, efforts are
needed to guarantee a robust supply of drugs from differ-
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ent classes, as well as the worldwide availability of affordable and simple viral load and genotyping assays to
ensure long-term success of global ART programs.
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